Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pere Gascon

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patientsCarme Font, Alberto Carmona-Bayonas, Aranzazu Fernández-Martinez, et al.
Acta Oto-Laryngologica|March 17, 2007
Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot studyJuan J Grau, Mariano Monzó, Miguel Caballero, et al.
Future Oncology (London, England)|April 29, 2017
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trialsNadia Harbeck, Pere Gascon, Clyde M Jones, et al.
Critical Reviews in Oncology/Hematology|August 12, 2018
A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemiaLuiz H Arantes, Jeffrey Crawford, Pere Gascon, et al.
Advances in Therapy|October 10, 2018
Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile NeutropeniaPaul Cornes, Pere Gascon, Stephen Chan, et al.
BMC Cancer|September 5, 2009
Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trialJohan Vansteenkiste, Michael Hedenus, Pere Gascon, et al.
Advances in Therapy|October 31, 2018
Correction to: Systematic Review and Meta-analysis of Short-versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile NeutropeniaPaul Cornes, Pere Gascon, Stephen Chan, et al.
Journal of Pain and Symptom Management|October 1, 2013
Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational studyAlexander Molassiotis, Matti Aapro, Mario Dicato, et al.
Medical Oncology (Northwood, London, England)|November 15, 2011
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trialJean-Luc Canon, Johan Vansteenkiste, Michael Hedenus, et al.
Expert Review of Anticancer Therapy|December 13, 2005
Clinical practice guidelines on antiemetics in oncologyEnrique Aranda Aguilar, Manuel Constenla Figueiras, Hernán Cortes-Funes, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patientsCarme Font, Alberto Carmona-Bayonas, Aranzazu Fernández-Martinez, et al.
Acta Oto-Laryngologica|March 17, 2007
Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot studyJuan J Grau, Mariano Monzó, Miguel Caballero, et al.
Future Oncology (London, England)|April 29, 2017
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trialsNadia Harbeck, Pere Gascon, Clyde M Jones, et al.
Critical Reviews in Oncology/Hematology|August 12, 2018
A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemiaLuiz H Arantes, Jeffrey Crawford, Pere Gascon, et al.
Advances in Therapy|October 10, 2018
Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile NeutropeniaPaul Cornes, Pere Gascon, Stephen Chan, et al.
BMC Cancer|September 5, 2009
Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trialJohan Vansteenkiste, Michael Hedenus, Pere Gascon, et al.
Advances in Therapy|October 31, 2018
Correction to: Systematic Review and Meta-analysis of Short-versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile NeutropeniaPaul Cornes, Pere Gascon, Stephen Chan, et al.
Journal of Pain and Symptom Management|October 1, 2013
Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational studyAlexander Molassiotis, Matti Aapro, Mario Dicato, et al.
Medical Oncology (Northwood, London, England)|November 15, 2011
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trialJean-Luc Canon, Johan Vansteenkiste, Michael Hedenus, et al.
Expert Review of Anticancer Therapy|December 13, 2005
Clinical practice guidelines on antiemetics in oncologyEnrique Aranda Aguilar, Manuel Constenla Figueiras, Hernán Cortes-Funes, et al.
Pageof 4